People: AEterna Zentaris Inc (AEZS.W)

AEZS.W on CBOE When Trading NASDAQ Global Select Market

2.05USD
20 May 2013
Price Change (% chg)

$-0.01 (-0.49%)
Prev Close
$2.06
Open
$2.05
Day's High
$2.05
Day's Low
$2.05
Volume
100
Avg. Vol
219
52-wk High
$5.51
52-wk Low
$1.72

Search Stocks

Summary

Name Age Since Current Position

Juergen Ernst

 74 2008 Independent Chairman of the Board

David Dodd

 62 2013 President, Chief Executive Officer, Director

Dennis Turpin

 2007 Chief Financial Officer, Senior Vice President

Paul Blake

 2007 Senior Vice President, Chief Medical Officer

Nicholas Pelliccione

 2007 Senior Vice President - Regulatory Affairs and Quality Assurance

Matthias Seeber

 2008 Senior Vice President - Administration and Legal Affairs

Elliot Shapiro

 2009 Corporate Secretary

Amelie Metivier

 2009 Assistant Secretary

Carolyn Egbert

 2012 Director

M. Marcel Aubut

 1996 Independent Director

Jose Dorais

 2006 Independent Director

Pierre Lapalme

 2009 Independent Director

Grard Limoges

 71 2004 Independent Director
» Insider Trading

Biographies

Name Description

Juergen Ernst

 Mr. Juergen H.L. Ernst is an Independent Chairman of the Board of AEterna Zentaris Inc. He has been Interim President and Chief Executive Officer from April 11, 2008 until August 31, 2008. He has served as a director on the Board since 2005. A seasoned executive with 20 years of pharmaceutical industry in the field of corporate development and pharmaceutical product marketing, Mr. Ernst was worldwide General Manager, Pharmaceutical Sector of Solvay S.A., before retiring in 2004. He has served as a director of Pharming Group N.V., Leiden, Netherlands since April 15, 2009.

David Dodd

 Mr. David A. Dodd has been appointed as the President, Chief Executive Officer, Director of Aeterna Zentaris Inc., with effect from April 15, 2013. Mr. Dodd's executive management experience in the pharmaceutical and biotechnology industries spans more than 35 years. From December 2007 to June 2009, Mr. Dodd was President, CEO and Chairman of BioReliance Corporation, a provider of biological safety and related testing services. From October 2006 to April 2009, he served as non-executive Chairman of Stem Cell Sciences Plc., where he oversaw the development and implementation of a strategic growth plan, implementation of an experienced executive team, and the sale of the Company to Stem Cells, Inc., in April 2009. During Mr. Dodd's six-year tenure as President, CEO and Director of Serologicals Corporation. Currently, he serves as Chair, Board of Directors, of GeoVax, Inc., a biotechnology company developing innovative, patented HIV/AIDS vaccines; as a Director on the Board of Aruna Biomedical, a privately-held life science development company focused on the development and commercialization of stem cell research products and services; and, as a Director on the Board of PNP Therapeutics, a clinical stage company, developing a novel nucleoside-booster treatment for solid tumor mass cancers. He also serves as CEO of RiversEdge BioVentures LLC ("RiversEdge"), which he founded in 2009. RiversEdge is an investment and advisory firm focused on the life sciences and pharmaceutical industry. Mr. Dodd holds Bachelor of Science and Master of Science degrees from Georgia State University, and completed the Harvard Business School of Advanced Management Program. His numerous public service activities include the American Foundation for Suicide Prevention, and the Board of Directors of the Institute of Bioengineering and Bioscience at Georgia Institute of Technology.

Dennis Turpin

 Mr. Dennis Turpin is Chief Financial Officer, Senior Vice President of AEterna Zentaris Inc., since August 2007. Prior to that, he served as Vice President and Chief Financial Officer since June 1999. Mr. Turpin joined Aeterna Zentaris in August 1996 as Director of Finance. Prior to that, he was Director in the tax department at Coopers Lybrand, now PricewaterhouseCoopers, from 1988 to 1996 and worked as an auditor from 1985 to 1988. Mr. Turpin earned his Bachelor’s degree in Accounting from Laval University in Québec. He obtained his license in accounting in 1985 and became a chartered accountant in 1987.

Paul Blake

 Dr. Paul Blake is Senior Vice President, Chief Medical Officer of AEterna Zentaris Inc., since August 2007. Prior to joining the Company, Dr. Blake was Chief Medical Officer of Avigenics, Inc. since January 2007. In 2005, he was Senior Vice President, Clinical Research and Regulatory Affairs at Cephalon, Inc. before being promoted to Executive Vice President, Worldwide Medical & Regulatory Operations. From 1992 to 1998, he held the position of Senior Vice President and Medical Director, Clinical Research and Development at SmithKline Beecham Pharmaceuticals (now GSK). Dr. Blake earned a medical degree from the London University, Royal Free Hospital. He was elected Fellow of the American College of Clinical Pharmacology, Fellow of the Faculty of Pharmaceutical Medicine, Royal College of Physicians in the UK, and he is a Fellow of the Royal College of Physicians in the UK.

Nicholas Pelliccione

 Dr. Nicholas J. Pelliccione is Senior Vice President - Regulatory Affairs and Quality Assurance of AEterna Zentaris Inc., since May 2007. In previous roles, Dr. Pelliccione has been responsible for the clinical/preclinical and CMC regulatory aspects of new drugs in the oncology, anti-infectives, cytokines and cardiovascular therapy areas, to several approvals. He served as Senior Vice President, Regulatory and Pharmaceutical Sciences at Chugai Pharma USA from May 2005 until March 2007. Prior to his experience at Chugai, Dr. Pelliccione spent 15 years at Schering Plough Corporation holding positions with responsibility from Manager of Regulatory Affairs, Oncology to, prior to his departure, Vice President, Global Regulatory Affairs, Chemistry, Manufacturing and Controls. Dr. Pelliccione holds a Ph.D. in Biochemistry from Mount Sinai School of Medicine, New York and a BS in Chemistry from Polytechnic University.

Matthias Seeber

 Mr. Matthias Seeber is Senior Vice President - Administration and Legal Affairs of AEterna Zentaris Inc., since December 2008. Mr. Seeber served as Managing Director of AEZS Germany since July 2003 up to his appointment. Prior to that, he had assumed the position of Investor Relations Manager of Altana AG, following several years in the banking industry with Deka Investment Management and Dresdner Bank AG. Mr. Seeber is a member of the Deutsche Vereinigung für Finanzanalyse und Asset Management (DVFA/CEFA). He obtained his M.B.A. from George Mason University Graduate School of Business Administration in the United States.

Elliot Shapiro

 Mr. Elliot Shapiro is Corporate Secretary of AEterna Zentaris Inc., since April 2009. In addition, Mr. Shapiro is a partner and a lawyer at the law firm of Norton Rose Canada LLP with a business law and transaction-oriented practice, where he has worked since 1999. He has been a member of the Barreau du Québec since 2000. Mr. Shapiro holds B.C.L. (1999), LL.B. (1999) and B.A. (1993) degrees from McGill University.

Amelie Metivier

 Ms. Amelie Metivier is Assistant Secretary of AEterna Zentaris Inc., since April 2009. In addition, Ms. Métivier is a lawyer at the law firm of Norton Rose Canada LLP with a business law and transaction-oriented practice, where she has worked since 2003. She is a member of the Barreau du Québec since 2006, and holds an LL.B. (2004) degree from Université de Montréal.

Carolyn Egbert

 Ms. Carolyn Egbert has been appointed as Director of Aeterna Zentaris Inc with effect from August 14, 2012. Her appointment is based on her experience in pharmacology, human resources and corporate governance with a focus on organizational design and global restructuring. She was also a on the Board of Directors of Solvay North America and its subsidiaries Peptisyntha and Solvay Enzymes.

M. Marcel Aubut

 Mr. Marcel Aubut is Independent Director of AEterna Zentaris Inc., since 1996. Mr. Aubut is a managing partner of Heenan Blaikie Aubut LLP, a law firm. These include, among others, Atomic Energy of Canada, Olymel L.P. (Olybro), Boralex Power Income Fund, Triton Electronik, Whole Foods Market Canada, Hydro-Québec (Executive Committee), Purolator Courier Ltd., Tremblant Resort, Cinar Inc., La Laurentienne générale, La Laurentienne vie, Investors Group Inc., Transforce Inc., Intra Continental Insurers Ltd., the National Hockey League Pension Society, Boréal Entreprises Premier CDN Ltée, Les Industries Amisco Ltée, Donohue Matane Inc., La Société de développement du Loisir et du Sport du Québec, the Canadian Olympic Committee, the Canadian Olympic Foundation, member of VANOC’s Audit Committee, Governance and Ethics Committee and Observer Team, Sodic Québec Inc., Innovatech Québec, Textile Dionne, Canada’s Sports Hall of Fame, the Committee for the 2002 Quebec City Olympic Games Bid, the Committee for the 2015 Toronto Pan American Games Bid, la Fondation Nordiques, etc. He has presided the establishment of industrial projects in the greater region of Quebec City.

Jose Dorais

 Mr. Jose P. Dorais is an Independent Director of AEterna Zentaris Inc., since 2006. Mr. Dorais is a partner of Miller Thomson Pouliot LLP where he practices administrative, corporate, business and international trade law. Over his 35-year career, he has worked in both the private and public sectors; in the latter he acted as Secretary to the Minister of Justice and as Secretary of the consulting committee on the Free Trade Agreement for the Quebec Provincial Government. Mr. Dorais has been a member of boards of directors, including the Société des Alcools du Québec, Biochem Pharma and St-Luc Hospital in Montreal. He is now a member of the Board of Alliance Films Inc., Investissement Québec and Chairman of the Board of Foster Wheeler Énergie Inc. He holds a law degree from the University of Ottawa and is a member of the Barreau du Québec.

Pierre Lapalme

 Mr. Pierre Lapalme is an Independent Director of AEterna Zentaris Inc., since December 2009. Mr. Lapalme has the course of his career held senior management positions in global life sciences companies. He is former Senior Vice-President, Sales and Marketing for Ciba-Geigy (which subsequently became Novartis) and former Chief Executive Officer and Chairman of the Board of Rhone-Poulenc Pharmaceuticals Inc. in Canada and in North America, as well as Executive Vice-President and Chief Executive Officer of Rhone-Poulenc-Rorer Inc. North America (now sanofi-aventis), where he supervised the development, manufacturing and sales of prescription products in North and Central America. Mr. Lapalme served on the Board of the National Pharmaceutical Council USA and was a Board member of the Pharmaceutical Manufacturers Association of Canada, where he played a role in reinstituting patent protection for pharmaceuticals. Until recently, he was Board member and Chairman of the Board of Sciele Pharma Inc. which was acquired by Shionogi and Co. Ltd. Mr. Lapalme is Chairman of the Board of Biomarin Inc., Chairman of the Board of Pediapharm Inc., Board member of Algorithme Pharma Inc. and Insy’s Therapeutics Inc., a Phoenix Arizona based specialty pharma Co. He studied at the University of Western Ontario and at INSEAD, France.

Grard Limoges

 Mr. Gerard A. Limoges is an Independent Director of AEterna Zentaris Inc., since 2004. Mr. Limoges served as the Deputy Chairman of Ernst & Young LLP Canada until his retirement in September 1999. After a career of 37 years with Ernst & Young, Mr. Limoges has been devoting his time as a director of a number of companies. Mr. Limoges began his career with Ernst & Young in Montreal in 1962. After graduating from the Management Faculty of Université de Montréal (HEC Montréal) in 1966, he wrote the CICA exams the same year (Honors: Governor General’s Gold Medal for the highest marks in Canada and Gold Medal of the Ordre des Comptables Agréés du Québec). He became a chartered accountant in 1967 and partner of Ernst & Young in 1971. After practicing as auditor since 1962 and partner since 1971, he was appointed Managing Partner of the Montreal Office in 1979 and Chairman for Quebec in 1984 when he joined the National Executive Committee. In 1992, he was appointed Vice-chairman of Ernst & Young Canada and the following year, Deputy Chairman of the Canadian firm. After retirement from public practice at the end of September 1999, he was appointed Trustee of the School board of Greater Montreal (1999), member of the Quebec Commission on Health Care and Social Services (2000-2001) and special advisor to the Rector of the University de Montreal and affiliate schools (2000-2003). Mr. Limoges became an FCA in 1984 and received the Order of Canada in 2002.

Basic Compensation

Name Fiscal Year Total

Juergen Ernst

 897,704

David Dodd

 --

Dennis Turpin

 549,197

Paul Blake

 607,515

Nicholas Pelliccione

 539,979

Matthias Seeber

 613,872

Elliot Shapiro

 --

Amelie Metivier

 --

Carolyn Egbert

 --

M. Marcel Aubut

 --

Jose Dorais

 --

Pierre Lapalme

 --

Grard Limoges

 --
As Of 30 Dec 2011

Insider Trading

» Full list on Insider Trading
Search Stocks